Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin‐induced type 1 diabetes

Studies suggest that soluble epoxide hydrolase (sEH) inhibition reduces end-organ damage in cardiovascular diseases. We hypothesize that sEH gene (Ephx2) knockout (KO) improves endothelial function and reduces renal injury in streptozotocin-induced diabetes. After 6 wk of diabetes, afferent arteriolar relaxation to acetylcholine was impaired in diabetic wild-type (WT) mice, as the maximum relaxation was 72% of baseline diameter in the WT but only 31% in the diabetic mice. Ephx2 KO improved afferent arteriolar relaxation to acetylcholine in diabetes as maximum relaxation was 58%. Urinary monocyte chemoattractant protein-1 (MCP-1) excretion significantly increased in diabetic WT mice compared with control (868 ± 195 vs. 31.5 ± 7 pg/day), and this increase was attenuated in diabetic Ephx2 KO mice (420 ± 98 pg/day). The renal phospho-IKK-to-IKK ratio and nuclear factor-κB were significantly decreased, and hemeoxygenase-1 (HO-1) expression increased in diabetic Ephx2 KO compared with diabetic WT mice. Renal NADPH oxidase and urinary thiobarbituric acid reactive substances excretion were reduced in diabetic Ephx2 KO compared with diabetic WT mice. Albuminuria was also elevated in diabetic WT mice compared with control (170 ± 43 vs. 37 ± 13 μg/day), and Ephx2 KO reduced this elevation (50 ± 15 μg/day). Inhibition of sEH using trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (tAUCB) also reduced renal inflammation and injury in diabetic WT mice. Furthermore, inhibition of HO with stannous mesoporphyrin negated the reno-protective effects of tAUCB or Ephx2 KO during diabetes. These data demonstrate that Ephx2 KO improves endothelial function and reduces renal injury during diabetes. Additionally, our data also suggest that activation of HO-1 contributes to improved renal injury in diabetic Ephx2 KO mice.

[1]  S. Imaoka,et al.  Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression. , 2009, Drug metabolism and pharmacokinetics.

[2]  B. Hammock,et al.  Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. , 2006, Life sciences.

[3]  J. Lawler,et al.  Thrombospondin-1 Is an Endogenous Activator of TGF-β in Experimental Diabetic Nephropathy In Vivo , 2007, Diabetes.

[4]  R. Atkins,et al.  Macrophage accumulation in human progressive diabetic nephropathy , 2006, Nephrology.

[5]  B. Hammock,et al.  Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. , 2009, American journal of physiology. Renal physiology.

[6]  N. Abraham,et al.  Heme oxygenase: the key to renal function regulation. , 2009, American journal of physiology. Renal physiology.

[7]  R. Atkins,et al.  Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  P. Pratt,et al.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. , 1996, Circulation research.

[9]  J. Pollock,et al.  Distinct Actions of Endothelin A-Selective Versus Combined Endothelin A/B Receptor Antagonists in Early Diabetic Kidney Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.

[10]  J. Falck,et al.  Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function , 2006, Circulation research.

[11]  Maristela L Onozato,et al.  Suppressing renal NADPH oxidase to treat diabetic nephropathy , 2007, Expert opinion on therapeutic targets.

[12]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[13]  M. Clare-Salzler,et al.  Eicosanoid Imbalance in the NOD Mouse Is Related to a Dysregulation in Soluble Epoxide Hydrolase and 15‐PGDH Expression , 2005, Annals of the New York Academy of Sciences.

[14]  Sampathkumar Anandan,et al.  Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single‐ and Multiple‐Dose Studies in Healthy Human Subjects , 2012, Journal of clinical pharmacology.

[15]  Sun Young Park,et al.  Increased Expression and Activity of 12-Lipoxygenase in Oxygen-Induced Ischemic Retinopathy and Proliferative Diabetic Retinopathy , 2011, Diabetes.

[16]  J. Shyy,et al.  The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Zeldin,et al.  Increased CYP2J3 Expression Reduces Insulin Resistance in Fructose-Treated Rats and db/db Mice , 2010, Diabetes.

[18]  M. Wellner,et al.  A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. , 2004, The American journal of pathology.

[19]  H. Krum,et al.  Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. , 2007, American journal of physiology. Heart and circulatory physiology.

[20]  S. Chakrabarti,et al.  Diabetes-induced Activation of Nuclear Transcriptional Factor in the Retina, and its Inhibition by Antioxidants , 2003, Free radical research.

[21]  Y. Jeon,et al.  Involvement of NF-κB in High Glucose-induced Alteration of a-methyl-D-glucopyranoside (α-MG) Uptake in Renal Proximal Tubule Cells , 2003, Cellular Physiology and Biochemistry.

[22]  E. Inscho,et al.  Chemokine Receptor 2b Inhibition Provides Renal Protection in Angiotensin II–Salt Hypertension , 2007, Hypertension.

[23]  John V Pearson,et al.  Identification of PVT1 as a Candidate Gene for End-Stage Renal Disease in Type 2 Diabetes Using a Pooling-Based Genome-Wide Single Nucleotide Polymorphism Association Study , 2007, Diabetes.

[24]  S. Ledbetter,et al.  Transforming Growth Factor-&bgr;, 20-HETE Interaction, and Glomerular Injury in Dahl Salt-Sensitive Rats , 2005 .

[25]  S. Hwang,et al.  Inhibition or Deletion of Soluble Epoxide Hydrolase Prevents Hyperglycemia, Promotes Insulin Secretion, and Reduces Islet Apoptosis , 2010, Journal of Pharmacology and Experimental Therapeutics.

[26]  J. Imig.  Targeting Epoxides for Organ Damage in Hypertension , 2010, Journal of cardiovascular pharmacology.

[27]  B. Kestenbaum,et al.  Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. , 2007, Journal of the American Society of Nephrology : JASN.

[28]  N. Abraham,et al.  Heme oxygenase: a target gene for anti-diabetic and obesity. , 2008, Current pharmaceutical design.

[29]  B. Hammock,et al.  Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. , 2009, Clinical science.

[30]  K. Tomer,et al.  Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension‐induced renal injury in mice , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  B. Hammock,et al.  Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[32]  E. Inscho,et al.  Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy. , 2009, American journal of physiology. Renal physiology.

[33]  N. Abraham,et al.  Heme oxygenase-1 prevents superoxide anion-associated endothelial cell sloughing in diabetic rats. , 2004, Biochemical and biophysical research communications.

[34]  S. Ledbetter,et al.  Transforming Growth Factor-, 20-HETE Interaction , and Glomerular Injury in Dahl Salt-Sensitive Rats , 2005 .

[35]  D. Heudes,et al.  Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. , 2000, Diabetes.

[36]  K. Ley,et al.  Leukocyte recruitment and vascular injury in diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.

[37]  W. Brown,et al.  Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. , 2008, The American journal of cardiology.

[38]  J. Imig,et al.  Tumor Necrosis Factor α Blockade Increases Renal Cyp2c23 Expression and Slows the Progression of Renal Damage in Salt-Sensitive Hypertension , 2006 .

[39]  J. Pollock,et al.  TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats , 2008 .

[40]  J. Pollock,et al.  Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. , 2004, Journal of the American Society of Nephrology : JASN.

[41]  H. Makino,et al.  Role of macrophages in the pathogenesis of diabetic nephropathy. , 2001, Contributions to nephrology.

[42]  F. Gonzalez,et al.  Targeted Disruption of Soluble Epoxide Hydrolase Reveals a Role in Blood Pressure Regulation* , 2000, The Journal of Biological Chemistry.

[43]  K. Sharma,et al.  Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. , 2007, Seminars in nephrology.

[44]  J. Imig,et al.  Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. , 2006, Hypertension.

[45]  Trevor A. Mori,et al.  Induction of Heme Oxygenase-1 In Vivo Suppresses NADPH Oxidase–Derived Oxidative Stress , 2007, Hypertension.

[46]  B. Hammock,et al.  An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension , 2005, Hypertension.

[47]  S. Ryter,et al.  Carbon Monoxide Protects against Hyperoxia-induced Endothelial Cell Apoptosis by Inhibiting Reactive Oxygen Species Formation* , 2007, Journal of Biological Chemistry.

[48]  J. Imig,et al.  Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. , 2009, Clinical science.

[49]  R. Elston,et al.  Examination of association with candidate genes for diabetic nephropathy in a Mexican American population. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[50]  N. Abraham,et al.  Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. , 2006, American journal of physiology. Heart and circulatory physiology.

[51]  R. Stocker,et al.  Pharmacologic induction of heme oxygenase-1. , 2007, Antioxidants & redox signaling.

[52]  J. Falck,et al.  11,12-epoxyeicosatrienoic acid stimulates heme-oxygenase-1 in endothelial cells. , 2007, Prostaglandins & other lipid mediators.

[53]  J. Navarro-González,et al.  Pathogenic perspectives for the role of inflammation in diabetic nephropathy. , 2009, Clinical science.

[54]  J. Falck,et al.  Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[55]  R. Roman,et al.  Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension , 2004, Current opinion in nephrology and hypertension.

[56]  Paul D. Jones,et al.  Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation , 2009, British journal of pharmacology.

[57]  C. Wilcox,et al.  NADPH oxidases in the kidney. , 2006, Antioxidants & redox signaling.

[58]  J. Pollock,et al.  Endothelin Mediates Superoxide Production and Vasoconstriction through Activation of NADPH Oxidase and Uncoupled Nitric-Oxide Synthase in the Rat Aorta , 2005, Journal of Pharmacology and Experimental Therapeutics.